ALZN · Alzamend Neuro, Inc.
$1.33
+0.07 (+5.56%)
At close · Jul 24
Going-concern doubt
— flagged Jul 22, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors create substantial doubt about our ability to continue as a going concern for at least one year after the date that our audited financial statements are issued.”View the 10-K filed Jul 22, 2026
Market Cap
$6.37M
Shares
4.79M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Stephan S. Jackman | CEO | $468,288 |
| David J. Katzoff | CFO | $150,000 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Stephan S. Jackman | CEO | $443,617 |
| David J. Katzoff | CFO | $150,000 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Stephan S. Jackman | CEO | $2,223,611 |
| David J. Katzoff | CFO | $116,667 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Lien T. Escalona | CFO | $1,182,302 |
| Stephan S. Jackman | CEO | $473,125 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Stephan S. Jackman | CEO | $225,000 |
| Kenneth S. Cragun | Director | $100,000 |